Handshake and reconciliation! Novo Nordisk withdraws lawsuit, Wegovy officially launches on the Hims & Hers platform
Wallstreetcn·- Novo Nordisk has reached a partnership agreement with Hims & Hers Health, resolving a prolonged patent dispute. - This collaboration allows Hims to sell Novo's products, Ozempic and Wegovy, through its platform while Hims commits to halting the promotion of its generic GLP-1 drugs. - The agreement reflects a shift in Hims's strategy towards FDA-approved medications and aims to enhance the accessibility of these weight loss products amid increasing regulatory scrutiny.